Nanoengineering of Mesenchymal Stem Cells via Surface Modification for Efficient Cancer Therapy

Abstract

AbstractMesenchymal stem cells (MSCs) can be used for tumor‐specific delivery of small molecular weight anticancer drugs by using nanoparticle‐encapsulated forms of the drugs. Current approaches to incorporate nanoparticles in MSCs rely on nonspecific endocytosis of nanoparticles or their conjugation to the cell surface via endogenous amines and thiols. These methods result in sub‐optimal drug loading, which hinders the widespread application of MSCs as drug carriers. An advanced nanoengineering strategy is reported here that involves generation of MSCs expressing azide functional groups on their surface and conjugation of dibenzyl cyclooctyne‐functionalized nanoparticles to the azide groups using copper‐free click chemistry. This novel strategy significantly improves the payload capacity of MSCs (≈48 pg of paclitaxel (PTX) per cell) relative to that reported previously (<1–20 pg per cell), without affecting their native phenotype. In vivo, the nanoengineered MSCs significantly inhibit tumor growth (p < 0.05) and improve survival (p < 0.0001) compared to free or nanoparticle encapsulated PTX and Abraxane in an orthotopic ovarian tumor model. In summary, the nanoengineering strategy reported here allows for improved delivery and anticancer efficacy of conventional chemotherapeutic agents using MSCs as drug carriers.